ICU kidney dialysis: which blood thinner dose works best?

NCT ID NCT07469072

Recruiting now Disease control Sponsor: Zhujiang Hospital Source: ClinicalTrials.gov ↗

First seen Mar 15, 2026 · Last updated Apr 30, 2026 · Updated 6 times

Summary

This study looks at two different starting doses of a blood thinner called nafamostat in ICU patients who need continuous kidney dialysis. The goal is to see which dose keeps the dialysis filter working longer without causing dangerous bleeding. About 92 adults will be randomly assigned to receive either 20 mg/h or 50 mg/h of the drug, and doctors will adjust the dose as needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Department of Critical Care Medicine of Zhujiang Hospital,Southern Medical University
RECRUITING

Guangzhou, Guangdong, 510282, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT)